Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma

BACKGROUND: Pemigatinib is an inhibitor of the fibroblast growth factor receptor (FGFR), recently approved for the treatment of cholangiocarcinoma. FGFR retinopathy is a newly recognized entity, with only two other FGFR inhibitors reported to cause serous retinopathy. Herein, we describe the first p...

Descripción completa

Detalles Bibliográficos
Autores principales: Alekseev, Oleg, Ojuok, Effy, Cousins, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067404/
https://www.ncbi.nlm.nih.gov/pubmed/33892812
http://dx.doi.org/10.1186/s40942-021-00305-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067404/
https://www.ncbi.nlm.nih.gov/pubmed/33892812
http://dx.doi.org/10.1186/s40942-021-00305-9

Ejemplares similares